Company Profile
Agenus Stock Price, News & Catalysts
- Ticker:
- AGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.49 USD (-14.20%)
Close
Last updated: October 6, 2026
141M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, AGEN closed down 14.2% at $7.49. No new same-company headline was identified in the current news window.
Company overview
Clinical-Stage Immuno-Oncology Company
Agenus develops antibody-based therapies intended to activate innate and adaptive immunity, overcome tumor immune evasion, and extend immunotherapy to cancers that respond poorly to conventional checkpoint blockade.
Botensilimab Lead Antibody
Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to prime T cells, reduce intratumoral regulatory T cells, activate myeloid cells, and generate durable immune memory.
BOT plus BAL Combination
Botensilimab is being developed with balstilimab, an anti-PD-1 antibody. The combination has been evaluated across multiple tumor types and is now prioritized for curative-intent treatment before surgery in high-risk microsatellite-stable colon cancer.
ROBBIN Phase 3 Strategy
ROBBIN is planned as a global randomized Phase 3 trial comparing neoadjuvant BOT plus BAL followed by surgery with surgery and standard management alone in high-risk Stage II and Stage III MSS colon cancer.
Access and Manufacturing Infrastructure
Agenus supports pre-commercial BOT plus BAL access through authorized programs in selected countries. A strategic manufacturing collaboration with Zydus provides dedicated U.S. biologics capacity, while Agenus retains interests in additional immunotherapy and vaccine-adjuvant businesses.
Future catalysts
- Longer-term follow-up manuscripts from the NEST and UNICORN studies in the second half of 2026.
- Investigator-sponsored BOT plus BAL presentations at ESMO 2026.
- Initiation and first-patient dosing of the Phase 3 ROBBIN trial in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Agenus (AGEN)?
Agenus (AGEN) most recently closed at 7.49 USD, a -14.20% move versus the previous session.
What is the market cap of Agenus (AGEN)?
Agenus currently has a market capitalization of 141M USD on BioPharmSignal.
What does Agenus do?
Clinical-Stage Immuno-Oncology Company Agenus develops antibody-based therapies intended to activate innate and adaptive immunity, overcome tumor immune evasion, and extend immunotherapy to cancers that respond poorly to conventional checkpoint blockade. Botensilimab Lead Antibody Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed...
On which exchange is AGEN stock listed?
Agenus (AGEN) is associated with NASDAQ, United States, Biopharma.
What is CTLA-4?
Botensilimab Lead Antibody Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to prime T cells, reduce intratumoral regulatory T cells, activate myeloid cells, and generate durable immune memory.
Which conditions is Agenus targeting with CTLA-4?
Agenus is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Agenus describe recent progress with CTLA-4?
Longer-term follow-up manuscripts from the NEST and UNICORN studies in the second half of 2026. Investigator-sponsored BOT plus BAL presentations at ESMO 2026. Initiation and first-patient dosing of the Phase 3 ROBBIN trial in the first quarter of 2027.
What is PD-1?
BOT plus BAL Combination Botensilimab is being developed with balstilimab, an anti-PD-1 antibody.